CD69 and myeloid sarcoma: Opposite to findings with FTY treatment, NTZ induced a significant increase of CD8+CD20+ cell frequency in peripheral blood [16] and of the relative frequency and absolute number of CD20+ T cells when compared to untreated patients [5], with a minor effect on their phenotype consisting of a reduction of the relative expression of the adhesion molecule CD49d and activation marker CD69 on both CD4+ and CD8+ cells compared to untreated MS; again, no differences in pro-inflammatory cytokines secretion were observed compared to untreated MS, except for a reduction of IL-17 [16].